dc.contributor.advisor | Dina, Sarah | |
dc.contributor.advisor | Edianto, Deri | |
dc.contributor.author | Lubis, Juhriyani M | |
dc.date.accessioned | 2021-07-14T06:46:25Z | |
dc.date.available | 2021-07-14T06:46:25Z | |
dc.date.issued | 2015 | |
dc.identifier.uri | http://repositori.usu.ac.id/handle/123456789/36032 | |
dc.description.abstract | Introduction: Gestational Trophoblastic Neoplasia is a malignancy that is
very sensitive to methotrexate, but the effectiveness is limited by the
resistance. Monitoring of serum β-hCG during chemotherapy is important
to know the success of chemotherapy and prediction the chemoresistance.
Therefore, we need to know the regression curve of serum β-hCG for early
identification of methotrexate resistance.
Objective: To determine the regression curve of serum β-hCG patients
with low-risk gestational trophoblastic neoplasia who were undergoing
single methotrexate chemotherapy at RSUP. H. Adam Malik Medan.
Methods: This study is a descriptive research with case series design,
which was performed on 34 patient’s medical records low risk gestational
trophoblastic neoplasia who received a single methotrexate chemotherapy
from January 2010 - December 2014. The parameters were assessed
were age, parity, anatomical pathology results, low risk FIGO scores,
presence or absence of metastasis, and the levels of pre-chemotherapy β-
hCG as a prognostic factor. The level of β-hCG serum curve of complete
remission group and resistance groups plotted in the curve and analyzed
descriptively.
Results: 2.5% of patients achieved normal value of β-hCG after receiving
2nd cycle of methotrexate, 50% of patients achieved normal value of β-
hCG after 4th cycle and 97.5% of patients achieved normal value of β-hCG
after 10th cycle. There are variations of β-hCG regression in the 50th
percentile group, where there is an increase in 8th cycle and returned to
normal in 9th cycle. Before starting chemotherapy, 2 (28.5%) of the 7
patients of MTX-resistant group are above the 97,5th percentile of
complete remission group. Before entering the 2nd cycle, 3 (42.8%) of the
7 patients are above 9.75th percentile. Before entering the 4th cycle, 5
(100%) of 5 patients who were still undergoing chemotherapy until the end
of the cycle are above the 97.5th percentile.
Conclusion: β-hCG regression curve of complete remission group reach
to normal level faster than MTX resistant group’s curve. | en_US |
dc.description.abstract | Pendahuluan: Penyakit trofoblas ganas adalah keganasan yang sangat
sensitive terhadap kemoterapi metotrexat, tetapi efektifitas metotrexat
dibatasi oleh resistensi. Pemantauan β-hCG serum selama pemberian
kemoterapi penting untuk mengetahui keberhasilan kemoterapi dan
prediksi kemoresistensi. Oleh karena itu, perlu diketahui kurva regresi β-
hCG serum untuk identifikasi resistensi metotrexat secara dini.
Tujuan:Untuk mengetahui kurva regresi β-hCG serum penderita penyakit
trofoblas ganas resiko rendah yang menjalani kemoterapi metotrexat
tunggal di RSUP. H. Adam Malik Medan.
Metode: Penelitian ini merupakan penelitian deskriptif dengan design
case series, yang dilakukan pada 34 data rekam medis penderita penyakit
trofoblas ganas risiko rendah yang mendapat kemoterapi metotrexat
tunggal mulai Januari 2010 - Desember 2014. Parameter yang dinilai
adalah usia, paritas, hasil patologi anatomi, skor FIGO resiko rendah, ada
tidaknya metastasis, dan kadar β-Hcg pra kemoterapi sebagai faktor
prognostik. Kadar kurva β-hCG serum kelompok remisi komplit dan
kelompok resistensi metotrexat diplot dalam kurva dan dianalisis secara
deskriptif.
Hasil: 2,5 % pasien mencapai nilai β-hCG normal setelah mendapat
metotrexat siklus ke-2, 50% pasien mencapai nilai β-hCG normal setelah
siklus ke 4 dan 97,5 % pasien mencapai nilai β-hCG normal setelah siklus
ke 10. Terdapat variasi regresi β-hCG pada kelompok persentil 50,
dimana terjadi kenaikan pada siklus ke-8 dan kembali normal di siklus 9.
Sebelum memulai kemoterapi, didapat 2 (28,5%) dari 7 pasien kelompok
resisten MTX yang berada diatas garis persentil 97.5 kelompok remisi
komplit. Sebelum memasuki siklus ke-2, 3 (42,8%) dari 7 pasien berada di
atas garis persentil 9,75. Sebelum memasuki siklus ke 4, 5 (100%) dari 5
pasien yang masih menjalani kemoterapi berada diatas garis persentil
97.5 sampai akhir siklus ditegakkan resisten MTX. | en_US |
dc.language.iso | id | en_US |
dc.publisher | Universitas Sumatera Utara | en_US |
dc.subject | penyakit tropoblas ganas | en_US |
dc.subject | metotreksat | en_US |
dc.subject | kurva regresi β-hCG | en_US |
dc.title | Kurva regresi β - Human Chorionic Gonadotropin Serum pada Penderita Penyakit Trofoblas Ganas Resiko Rendah yang Mendapat Kemoterapi Metotrexat Tunggal di RSUP. H. Adam Malik Medan | en_US |
dc.type | Thesis | en_US |
dc.identifier.nim | Juhriyani M. Lubis | |
dc.description.pages | 80 Halaman | en_US |
dc.description.type | Tesis Magister | en_US |